Adverse event profiles and time to onset and resolution with tremelimumab ( t) plus durvalumab (d) in patients with unresectable hepatocellular carcinoma (uhcc) in the phase 3 himalaya trial
| dc.contributor.author | De Toni, E. M. | |
| dc.contributor.author | Sangro, B. | |
| dc.contributor.author | Chan, S. L. | |
| dc.contributor.author | Kudo, M. | |
| dc.contributor.author | Kelley, R. K. | |
| dc.contributor.author | -K, Kang Y. | |
| dc.contributor.author | Rimassa, L. | |
| dc.contributor.author | Varela Calvo, María | |
| dc.contributor.author | Dayyani, F. | |
| dc.contributor.author | Makowsky, M. | |
| dc.contributor.author | Marcovitz, M. | |
| dc.contributor.author | Mccoy, C. L. | |
| dc.contributor.author | Negro, A. | |
| dc.contributor.author | Abou Alfa, G. | |
| dc.date.accessioned | 2024-07-11T07:29:24Z | |
| dc.date.available | 2024-07-11T07:29:24Z | |
| dc.date.issued | 2023 | |
| dc.identifier.issn | 2296-5270 | |
| dc.identifier.issn | 2296-5262 | |
| dc.identifier.uri | https://hdl.handle.net/10651/73147 | |
| dc.format.extent | p. 239-240 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Oncology Research and Treatment | |
| dc.rights | ©, | |
| dc.source | WOS:001091456900523 | |
| dc.title | Adverse event profiles and time to onset and resolution with tremelimumab ( t) plus durvalumab (d) in patients with unresectable hepatocellular carcinoma (uhcc) in the phase 3 himalaya trial | |
| dc.type | conference output |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||